Literature DB >> 27134691

HIV DYNAMICS AND NATURAL HISTORY STUDIES: JOINT MODELING WITH DOUBLY INTERVAL-CENSORED EVENT TIME AND INFREQUENT LONGITUDINAL DATA.

Li Su1, Joseph W Hogan2.   

Abstract

Hepatitis C virus (HCV) coinfection has become one of the most challenging clinical situations to manage in HIV-infected patients. Recently the effect of HCV coinfection on HIV dynamics following initiation of highly active antiretroviral therapy (HAART) has drawn considerable attention. Post-HAART HIV dynamics are commonly studied in short-term clinical trials with frequent data collection design. For example, the elimination process of plasma virus during treatment is closely monitored with daily assessments in viral dynamics studies of AIDS clinical trials. In this article instead we use infrequent cohort data from long-term natural history studies and develop a model for characterizing post-HAART HIV dynamics and their associations with HCV coinfection. Specifically, we propose a joint model for doubly interval-censored data for the time between HAART initiation and viral suppression, and the longitudinal CD4 count measurements relative to the viral suppression. Inference is accomplished using a fully Bayesian approach. Doubly interval-censored data are modeled semiparametrically by Dirichlet process priors and Bayesian penalized splines are used for modeling population-level and individual-level mean CD4 count profiles. We use the proposed methods and data from the HIV Epidemiology Research Study (HERS) to investigate the effect of HCV coinfection on the response to HAART.

Entities:  

Keywords:  AIDS; antiviral treatment; interval censoring; semiparametric regression

Year:  2011        PMID: 27134691      PMCID: PMC4851349          DOI: 10.1214/10-AOAS391

Source DB:  PubMed          Journal:  Ann Appl Stat        ISSN: 1932-6157            Impact factor:   2.083


  20 in total

1.  Analysis of doubly-censored survival data, with application to AIDS.

Authors:  V De Gruttola; S W Lagakos
Journal:  Biometrics       Date:  1989-03       Impact factor: 2.571

2.  Design and baseline participant characteristics of the Human Immunodeficiency Virus Epidemiology Research (HER) Study: a prospective cohort study of human immunodeficiency virus infection in US women.

Authors:  D K Smith; D L Warren; D Vlahov; P Schuman; M D Stein; B L Greenberg; S D Holmberg
Journal:  Am J Epidemiol       Date:  1997-09-15       Impact factor: 4.897

3.  Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study.

Authors:  G Greub; B Ledergerber; M Battegay; P Grob; L Perrin; H Furrer; P Burgisser; P Erb; K Boggian; J C Piffaretti; B Hirschel; P Janin; P Francioli; M Flepp; A Telenti
Journal:  Lancet       Date:  2000-11-25       Impact factor: 79.321

4.  Effect of hepatitis C infection on progression of HIV disease and early response to initial antiretroviral therapy.

Authors:  Patrick S Sullivan; Debra L Hanson; Eyasu H Teshale; Linda L Wotring; John T Brooks
Journal:  AIDS       Date:  2006-05-12       Impact factor: 4.177

Review 5.  An update on the neuropathology of HIV in the HAART era.

Authors:  J E Bell
Journal:  Histopathology       Date:  2004-12       Impact factor: 5.087

6.  Hepatitis C Virus prevalence among patients infected with Human Immunodeficiency Virus: a cross-sectional analysis of the US adult AIDS Clinical Trials Group.

Authors:  Kenneth E Sherman; Susan D Rouster; Raymond T Chung; Natasa Rajicic
Journal:  Clin Infect Dis       Date:  2002-02-06       Impact factor: 9.079

7.  Influence of hepatitis C virus infection on HIV-1 disease progression and response to highly active antiretroviral therapy.

Authors:  Jürgen K Rockstroh; Amanda Mocroft; Vincent Soriano; Cristina Tural; Marcello H Losso; Andrzej Horban; Ole Kirk; Andrew Phillips; Bruno Ledergerber; Jens Lundgren
Journal:  J Infect Dis       Date:  2005-08-11       Impact factor: 5.226

8.  Hepatitis C and progression of HIV disease.

Authors:  Mark S Sulkowski; Richard D Moore; Shruti H Mehta; Richard E Chaisson; David L Thomas
Journal:  JAMA       Date:  2002-07-10       Impact factor: 56.272

9.  Immunologic responses associated with 12 weeks of combination antiretroviral therapy consisting of zidovudine, lamivudine, and ritonavir: results of AIDS Clinical Trials Group Protocol 315.

Authors:  M M Lederman; E Connick; A Landay; D R Kuritzkes; J Spritzler; M St Clair; B L Kotzin; L Fox; M H Chiozzi; J M Leonard; F Rousseau; M Wade; J D Roe; A Martinez; H Kessler
Journal:  J Infect Dis       Date:  1998-07       Impact factor: 5.226

10.  Joint modelling of bivariate longitudinal data with informative dropout and left-censoring, with application to the evolution of CD4+ cell count and HIV RNA viral load in response to treatment of HIV infection.

Authors:  Rodolphe Thiébaut; Hélène Jacqmin-Gadda; Abdel Babiker; Daniel Commenges
Journal:  Stat Med       Date:  2005-01-15       Impact factor: 2.373

View more
  1 in total

1.  Bayesian joint modelling of longitudinal and time to event data: a methodological review.

Authors:  Maha Alsefri; Maria Sudell; Marta García-Fiñana; Ruwanthi Kolamunnage-Dona
Journal:  BMC Med Res Methodol       Date:  2020-04-26       Impact factor: 4.615

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.